Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. SARS-CoV-2 also known as 2019-nCoV, is a positive-sense single-stranded RNA virus and is believed to have zoonotic origins and has close genetic similarity to bat coronaviruses. The receptor binding domain (RBD) of spike protein of the SARS-CoV-2 virus binds Angiotensin-Converting Enzyme 2 (ACE2) to invade the host cells. Based on structural biology studies, the RBD can be oriented either in the up/standing or down/lying state with the up/standing state associated with higher pathogenicity.
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
Synonyms SARS-CoV-2 SP RBD, 2019-nCoV S1 RBD, SARS-CoV-2 S1 RBD
Description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. SARS-CoV-2 also known as 2019-nCoV, is a positive-sense single-stranded RNA virus and is believed to have zoonotic origins and has close genetic similarity to bat coronaviruses. The receptor binding domain (RBD) of spike protein of the SARS-CoV-2 virus binds Angiotensin-Converting Enzyme 2 (ACE2) to invade the host cells. Based on structural biology studies, the RBD can be oriented either in the up/standing or down/lying state with the up/standing state associated with higher pathogenicity.
Species SARS-CoV-2
Source Human
Tag Avi & His tag Biological Activity This protein is validated to bind with human ACE2 (Cat. No. Z03516) in functional ELISA assay.
Sequence Accession#QHD43416.1 ( Arg319-Ser591)
Properties
- Molecular Weight Predicted on protein sequence: 30 KD
- Formulation Liquid Component PBS 7.4, 0.5% PC300
- Storage This product can be stable for 6 months at 2-8?. Protect from light.
- Note For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
Applications The optimal dilution ratio should be determined by the end user for specific applications. ELISA 1:1000